Polaryx Therapeutics, Inc. Total Current Assets decreased by 32.3% to $3.50M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
A higher value relative to current liabilities indicates a strong safety margin for meeting short-term obligations.
The sum of all assets that are reasonably expected to be converted into cash or consumed within one year. This aggregate...
High-growth tech companies often maintain high current asset levels to support rapid scaling and R&D needs.
total_current_assets| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $5.17M | $3.50M |
| QoQ Change | — | -32.3% |